Expert Consensus on Clinical Application of Pingxuan Capsules
10.13422/j.cnki.syfjx.20250695
- VernacularTitle:平眩胶囊临床应用专家共识
- Author:
Yuer HU
1
;
Yanming XIE
1
;
Yaming LIN
2
;
Yuanqi ZHAO
3
;
Yihuai ZOU
4
;
Mingquan LI
5
;
Xiaoming SHEN
6
;
Wei PENG
7
;
Changkuan FU
1
;
Yuanyuan LI
1
Author Information
1. Institute of Basic Research in Clinical Medicine， China Academy of Chinese Medical Sciences，Beijing 100700，China
2. Yunnan Provincial Hospital of Traditional Chinese Medicine（TCM），Kunming 650103，China
3. Guangdong Provincial Hospital of TCM，Guangzhou 510120，China
4. Dongzhimen Hospital of Beijing University of Chinese Medicine，Beijing 100700，China
5. The Third Affiliated Hospital of Changchun University of Chinese Medicine，Changchun 130022，China
6. The First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450000，China
7. The Affiliated Hospital of Shandong University of TCM，Jinan 250144，China
- Publication Type:Journal Article
- Keywords:
Pingxuan capsules;
expert consensus;
vertigo;
ethnic medicine
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2025;31(1):201-210
- CountryChina
- Language:Chinese
-
Abstract:
As a patented characteristic medicine of Yi ethnic minority， Pingxuan capsules have the effects of nourishing the liver and kidney， pacifying the liver， and subduing Yang. With the main indications of dizziness， headache， palpitations， tinnitus， insomnia， dreaminess， waist and knee soreness caused by liver-kidney deficiency and liver Yang upward disturbance， Pingxuan capsules are widely used in the treatment of posterior circulation ischemic vertigo， vestibular migraine， benign paroxysmal positional vertigo. However， the current knowledge is limited regarding the efficacy， syndrome differentiation， and safety of this medicine. On the basis of summarizing the experience of clinicians and the existing evidence， this study invites clinical experts of traditional Chinese and Western medicine， pharmaceutical experts， and methodological experts from relevant fields across China to conduct evidence-based evaluation of Pingxuan capsules. The evaluation follows the Specifications for the Development of Clinical Expert Consensus on Chinese Patent Medicines issued by the Standardization Office of the China Association of Chinese Medicine， and reaches 5 recommendations and 16 consensus suggestions. The consensus clarifies the clinical applications， efficacy， dose， course of treatment， combination of medicines， precautions， and contraindications of Pingxuan capsules in the treatment of vertigo and explains the safety of clinical application. This consensus is applicable to clinicians （traditional Chinese medicine， Western medicine， and integrated traditional Chinese and Western medicine） and pharmacists in tertiary hospitals， secondary hospitals， and community-level medical and health institutions across China， providing a reference for the rational use of Pingxuan capsules in the treatment of vertigo. It is hoped that the promotion of this consensus can facilitate the rational use of drugs in clinical practice， reduce the risk of drug use， and give full play to the advantages of Pingxuan capsules in the treatment of vertigo diseases. This consensus has been reviewed and published by the China Association of Chinese Medicine， with the number GS/CACM330-2023.
